To Deliver Low Dose Intravenous Ketamine for Mood and Anxiety Disorders, a Recommended Treatment by Canadian Guidelines, Upon Clinic LicensingOAKVILLE, ON / ACCESSWIRE / March 23, 2022 / NeonMind Biosciences
VANCOUVER, BC / ACCESSWIRE / February 23, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind' or the "Company"), an integrated drug development and wellness company focused on